8-K: CorMedix to Acquire Melinta, Expanding Acute Care Portfolio

CorMedix Inc. announced a definitive agreement to acquire Melinta Therapeutics, LLC for $300 million upfront, significantly expanding its commercial product portfolio and projecting substantial revenue and EBITDA growth.

Summary

• CorMedix Inc. has entered into an Agreement and Plan of Merger to acquire Melinta Therapeutics, LLC.
• The upfront consideration for the acquisition totals $300 million, comprising $260 million in cash and $40 million in CorMedix common shares issued to Melinta shareholders.
• The cash consideration will be funded by a combination of CorMedix's existing cash on hand and the proceeds from a $150 million convertible notes offering.
• Melinta equityholders are eligible to receive contingent payments, including a regulatory milestone of up to $25 million for FDA approval of REZZAYO for prophylaxis of invasive fungal infections (if achieved by June 30, 2029), tiered royalties on REZZAYO U.S. net sales, and low-single-digit royalties on MINOCIN U.S. net sales.
• The transaction is expected to generate annual run-rate synergies of $35 million to $45 million.
• Pro forma 2025 combined revenues are estimated to be between $305 million and $335 million.
• Pro forma 2025 Synergized Adjusted EBITDA is projected to be between $150 million and $170 million.
• CorMedix reported Q2 2025 net revenue of $39.7 million from DefenCath sales, a significant increase from $0.8 million in Q2 2024.
• CorMedix's Q2 2025 net income was $19.8 million, or $0.29 per share, compared to a net loss of $14.2 million, or $0.25 per share, in Q2 2024.
• Melinta's total revenue for 2024 was $120 million, with an expected FY 2025 revenue of $125 million to $135 million.
• CorMedix's standalone DefenCath 2025 revenue guidance is $180 million to $200 million.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, driven by a transformative acquisition expected to significantly expand revenue, achieve substantial synergies, and be accretive to EPS. The strong Q2 2025 financial performance of CorMedix further reinforces this positive sentiment. While risks associated with integration and market conditions are acknowledged, the overall tone and projected financial benefits are overwhelmingly optimistic.

Positives

• The acquisition significantly expands and diversifies CorMedix's commercial product portfolio with seven innovative drug products and TOPROL-XL, establishing a strong presence in acute care settings.
• The transaction is expected to be near-term accretive to EPS, with double-digit accretion projected in 2026.
• The combined company is projected to achieve substantial financial scale with pro forma 2025 combined revenues of $305 million to $335 million and synergized adjusted EBITDA of $150 million to $170 million.
• REZZAYO offers significant growth opportunities through its ongoing Phase III study for prophylaxis of invasive fungal infections, with potential peak annual sales exceeding $200 million in this expanded indication.
• Upside growth potential exists from BARDA collaborations for BAXDELA and VABOMERE, supporting pediatric and biodefense programs.
• The acquisition creates a dynamic platform that can be leveraged to support additional products and expand as the combined company enters its next phase of business development.
• CorMedix's lead product, DefenCath, is expected to achieve peak annual sales of $150 million to $200 million in the TPN indication, with clinical studies commencing in 2025.

Negatives

• The convertible notes bear interest at 4.00% per annum, which will add to the company's debt service obligations.
• The transaction involves a substantial cash outlay of $260 million, requiring significant financing.
• The issuance of $40 million in CorMedix equity to Melinta shareholders and potential future share issuances upon conversion of notes could lead to dilution for existing CorMedix shareholders.

Risks

• The ultimate outcome of the acquisition of Melinta is uncertain.
• There is a risk that the conditions to the closing of the proposed transaction may not be satisfied in a timely manner or at all.
• The combined company may not be able to achieve the identified synergies of $35 million to $45 million annually.
• Integration of the Melinta business into CorMedix may be more difficult, time-consuming, or costly than expected.
• Operating costs, customer loss, and business disruption (including difficulties in maintaining relationships with employees, customers, or suppliers) may be greater than expected following the proposed transaction.
• Challenges may arise in retaining certain key employees of Melinta.
• The expected benefits and success of Melinta's products and product candidates are not guaranteed.
• Potential litigation relating to the transaction could be instituted against CorMedix or its directors.
• Rating agency actions and CorMedix's ability to access shortand long-term debt markets on a timely and affordable basis could be impacted.
• General economic conditions that are less favorable than expected, geopolitical developments, and changes in international trade policies and relations (including tariffs) could adversely affect the business.
• The ability of the combined company's products and product candidates to compete effectively against current and future competitors is a risk.
• Hedging activities by Company Members and their affiliates could reduce the value of existing stockholders' equity interests in CorMedix.
• The issuance of shares upon conversion of the notes or warrants may require stockholder approval if it exceeds 19.99% of the aggregate number of shares of Common Stock issued and outstanding, and failure to obtain such approval could limit the company's ability to issue shares.

Future Outlook

CorMedix anticipates the acquisition of Melinta Therapeutics will significantly expand its commercial product portfolio and drive future growth, with pro forma 2025 combined revenues estimated at $305 million to $335 million and synergized adjusted EBITDA of $150 million to $170 million. The company expects the transaction to be near-term accretive to EPS, with double-digit accretion in 2026. Key growth drivers include the ongoing Phase III study for REZZAYO prophylaxis, expected to complete in 1H 2026 with potential peak annual sales exceeding $200 million, and the commencement of DefenCath clinical studies in TPN and pediatric populations in 2025, with TPN peak annual sales potentially reaching $150 million to $200 million.

Management Comments

• "This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth." Joseph Todisco, CEO of CorMedix Inc.
• "I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena." Joseph Todisco, CEO of CorMedix Inc.
• "This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future." Joseph Todisco, CEO of CorMedix Inc.
• "The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company's evolution." Christine Ann Miller, President and CEO of Melinta Therapeutics.
• "Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability." Christine Ann Miller, President and CEO of Melinta Therapeutics.
• "CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I'm confident that Melinta's commercial excellence and proven track record will augment CorMedix's team and track record of operational execution and success, to create an even stronger platform for future growth." Christine Ann Miller, President and CEO of Melinta Therapeutics.

Industry Context

The acquisition aligns with a trend towards consolidation and diversification in the specialty pharmaceutical sector, particularly within acute care and infectious disease. By combining CorMedix's DefenCath with Melinta's portfolio of seven commercial products, the combined entity aims to establish a robust commercial hospital/acute care platform, leveraging existing infrastructure for expanded reach and future product integration. This strategy seeks to enhance financial scale and create multiple growth opportunities through pipeline expansion and government collaborations, positioning the company for both organic and inorganic growth in a competitive market.

Corporate Governance

Related Party Transactions

• Deerfield Private Design Fund IV, L.P. and Deerfield Private Design Fund III, L.P. (Consenting Melinta Members) are receiving $40 million worth of CorMedix common shares as part of the merger consideration.
• Deerfield is participating in the $150 million convertible debt financing.
• The Consenting Melinta Members and certain Company Optionholders will be eligible to receive contingent payments, including a regulatory milestone and tiered royalties on REZZAYO and MINOCIN U.S. net sales.

Stakeholder Impact

• **Shareholders (CorMedix):** Expected to benefit from significant revenue growth, expanded product portfolio, and projected double-digit EPS accretion in 2026, but face potential dilution from the convertible notes and equity issuance.
• **Shareholders (Melinta):** Will receive $260 million in cash and $40 million in CorMedix equity upfront, with potential for additional contingent milestone and royalty payments.
• **Employees (Melinta):** Will be integrated into the combined company, with a focus on retaining key personnel, and their existing severance plans and bonus plans will be honored.
• **Customers:** Will gain access to a broader and more diversified portfolio of acute care and infectious disease therapies from a single, larger entity.
• **Creditors (Convertible Noteholders):** Will hold senior, unsecured obligations of CorMedix, bearing 4.00% interest, with conversion rights and potential redemption options.

Next Steps

• The Merger is expected to close in September 2025, subject to HSR clearance and other customary conditions.
• The $150 million convertible senior notes are expected to be issued on August 12, 2025.
• CorMedix will seek stockholder approval for share issuances exceeding the Nasdaq Exchange Cap, if required.
• Enrollment in the Phase III trial of REZZAYO for prophylaxis is expected to be completed by October 31, 2025.
• The Phase III study for REZZAYO prophylaxis is expected to be completed in 1H 2026, potentially leading to a supplemental New Drug Application (sNDA).
• CorMedix commenced clinical studies for DefenCath in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025.
• Anticipated completion of the DefenCath TPN study and NDA submission is in late 2026 / early 2027.
• CorMedix intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas.
• Following the Effective Time, CorMedix will comply with the terms and conditions of the TOPROL Acquisition Agreement.

Key Dates

Recommendation

The acquisition of Melinta Therapeutics is a highly strategic and financially compelling move for CorMedix. The immediate and substantial increase in revenue base, coupled with significant synergy projections ($35M-$45M annually) and expected double-digit EPS accretion in 2026, positions the combined entity for robust financial performance. The diversified portfolio of eight commercial products, particularly the growth potential from REZZAYO's expanded indication (>$200M peak sales) and DefenCath's TPN indication (>$150M peak sales), offers multiple avenues for long-term value creation. While integration risks exist, the strong financial outlook and strategic fit make this a highly attractive investment opportunity.

Keywords

Biopharmaceutical, Acquisition, Melinta Therapeutics, CorMedix, DefenCath, REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, TOPROL-XL, Infectious Disease, Acute Care, Convertible Notes, Merger, Pharmaceuticals, Healthcare, Biotech